Rocatinlimab Halt Puts Spotlight On Amgen Pipeline Risks And Valuation

2026-04-01 18:19:05

Amgen and Kyowa Kirin have ceased all clinical trials for rocatinlimab due to newly identified safety concerns, including cases of malignancy. This decision removes a significant immunology asset from Amgen’s pipeline, raising questions about the company’s R&D strategy and risk profile for late-stage assets. Despite this setback, Amgen’s stock is currently trading near analyst targets and is flagged as undervalued by Simply Wall St, although it has experienced recent negative momentum.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes